Bristol Myers Shares Preliminary Phase 3 ADEPT Data for KarXT
Open-label Phase 3 ADEPT-1 and ADEPT-3 data showed improvements in hallucinations, delusions and disease symptoms.
Open-label Phase 3 ADEPT-1 and ADEPT-3 data showed improvements in hallucinations, delusions and disease symptoms.